Airet Solution

Pronunciation: al-BUE-ter-ol
Generic Name: Albuterol
Brand Name: Examples include Airet and Proventil

Airet Solution is used for:

Treating breathing problems in patients who have asthma or certain other airway diseases. It may also be used for other conditions as determined by your doctor.

Airet Solution is a sympathomimetic (beta agonist) bronchodilator. It works by relaxing the smooth muscle in the airway, which allows air to flow in and out of the lungs more easily.

Do NOT use Airet Solution if:

• you are allergic to any ingredient in Airet Solution


• you are using another short-acting sympathomimetic bronchodilator (eg, metaproterenol) or epinephrine

Contact your doctor or health care provider right away if any of these apply to you.

Before using Airet Solution:

Some medical conditions may interact with Airet Solution. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

• if you are pregnant, planning to become pregnant, or are breast-feeding


• if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines, foods, or other substances


• if you have a history of heart problems, (eg, fast or irregular heartbeat, heart failure), blood vessel problems, high blood pressure, or low blood potassium levels


• if you have a history of seizures, diabetes, an overactive thyroid, kidney problems, or an adrenal gland tumor (pheochromocytoma)


• if you have ever had an unusual reaction to another sympathomimetic medicine (eg, pseudoephedrine)


• if you are taking a monoamine oxidase inhibitors (MAOI) (eg, phenelzine), or tricyclic antidepressant (eg, amitriptyline), or if you have taken either of these medicines within the last 14 days

Some MEDICINES MAY INTERACT with Airet Solution. Tell your health care provider if you are taking any other medicines, especially any of the following:

• Diuretics (eg, furosemide, hydrochlorothiazide) because the risk of low blood potassium levels may be increased


• Catechol-O-methyltransferase (COMT) inhibitors (eg, entacapone), epinephrine, MAOIs (eg, phenelzine), short-acting sympathomimetic bronchodilators (eg, metaproterenol), stimulants (eg, amphetamine), sympathomimetics (eg, pseudoephedrine), or tricyclic antidepressants (eg, amitriptyline) because they may increase the risk of Airet Solution's side effects


• Beta-blockers (eg, propranolol) because they may decrease Airet Solution's effectiveness


• Digoxin because its effectiveness may be decreased by Airet Solution

This may not be a complete list of all interactions that may occur. Ask your health care provider if Airet Solution may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Airet Solution:

Use Airet Solution as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• An extra patient leaflet is available with Airet Solution. Talk to your pharmacist if you have questions about this information.


• Airet Solution is for inhalation only. Do not get it in the eyes. If you get Airet Solution in the eyes, rinse immediately with cool tap water.


• Remove a vial from the foil pouch. Place the remaining vials back into the pouch for storage.


• Do not use Airet Solution if it contains particles, is cloudy or discolored, or if the vial is cracked or damaged.


• To use Airet Solution, twist open the top of the vial and pour the entire contents into the nebulizer reservoir.


• Connect the nebulizer reservoir to the mouthpiece or face mask. Connect the nebulizer to the compressor.


• Sit in a comfortable, upright position. Place the mouthpiece in your mouth (or put on the face mask) and turn on the nebulizer.


• Breathe as calmly, deeply, and evenly as possible until no more mist is formed in the nebulizer chamber (about 5 to 15 minutes).


• Clean the nebulizer according to the instructions. Failure to properly clean the nebulizer could lead to bacteria entering the medicine. This may lead to an infection. To avoid bacteria entering the medicine, use the entire contents right after opening the vial for the first time.


• Do not stop using Airet Solution without checking with your doctor.


• Do not mix Airet Solution with other medicines in the nebulizer unless directed otherwise by your doctor.


• If you miss a dose of Airet Solution and you are using it regularly, use it as soon as possible. If several hours have passed or if it is nearing time for the next dose, do not double the dose to catch up, unless advised by your health care provider. Do not use 2 doses at once.

Ask your health care provider any questions you may have about how to use Airet Solution.

Important safety information:

• Airet Solution may cause dizziness. These effects may be worse if you take it with alcohol or certain medicines. Use Airet Solution with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.


• Airet Solution may sometimes cause severe breathing problems right after you use a dose. If this happens, seek medical care at once.


• If your usual dose does not work well, your symptoms become worse, or you need to use it more often than normal, contact your doctor at once. This may be a sign of seriously worsening asthma. Your doctor may need to change your dose or medicine.


• Airet Solution should work for up to 6 hours. Do NOT use more than the recommended dose or use more often than prescribed without checking with your doctor. The risk of severe heart problems and sometimes death may be increased with overuse of Airet Solution.


• Airet Solution may cause dry mouth or an unpleasant taste in your mouth. Rinsing your mouth with water after each dose may help relieve these effects.


• Tell your doctor or dentist that you take Airet Solution before you receive any medical or dental care, emergency care, or surgery.


• Check with your doctor before using any other inhaled medicines while you are using Airet Solution.


• Diabetes patients - Airet Solution may affect your blood sugar. Check blood sugar levels closely. Ask your doctor before you change the dose of your diabetes medicine.


• When your medicine supply begins to run low, call your doctor or pharmacy as soon as possible for a refill.


• Use Airet Solution with caution in the ELDERLY; they may be more sensitive to its effects.


• Airet Solution should be used with extreme caution in CHILDREN younger than 2 years old; safety and effectiveness in these children have not been confirmed.


• Caution is advised when using Airet Solution in CHILDREN; they may be more sensitive to its effects.


• PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Airet Solution while you are pregnant. It is not known if Airet Solution is found in breast milk. If you are or will be breast-feeding while you use Airet Solution, check with your doctor. Discuss any possible risks to your baby.

Possible side effects of Airet Solution:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Cough; dizziness; headache; nausea; nervousness; sinus inflammation; sore or dry throat; tremor; trouble sleeping; unusual taste in mouth; vomiting.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); chest pain; ear pain; fast or irregular heartbeat; new or worsened trouble breathing; pounding in the chest; severe headache or dizziness; unusual hoarseness; wheezing.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Airet side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include chest pain; fast or irregular heartbeat; seizures; severe headache or dizziness; severe or persistent nervousness or trouble sleeping; tremor.

Proper storage of Airet Solution:

Store Airet Solution between 36 and 77 degrees F (2 and 25 degrees C). Store in the protective foil pouch at all times. Store away from heat, moisture, and light. Do not store in the bathroom. Do not use after the expiration date on the container or box. Keep Airet Solution out of the reach of children and away from pets.

General information:

• If you have any questions about Airet Solution, please talk with your doctor, pharmacist, or other health care provider.


• Airet Solution is to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.


• Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Airet Solution. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Airet resources

• Airet Side Effects (in more detail)
• Airet Use in Pregnancy & Breastfeeding
• Airet Drug Interactions
• Airet Support Group
• 0 Reviews for Airet - Add your own review/rating

Compare Airet with other medications

• Asthma, acute
• Asthma, Maintenance
• Bronchospasm Prophylaxis
• COPD, Acute
• COPD, Maintenance

Agrylin

Pronunciation: an-AG-re-lide
Generic Name: Anagrelide
Brand Name: Agrylin

Agrylin is used for:

Treating patients with high blood platelet levels (thrombocythemia) due to bone marrow problems. It may also be used for other conditions as determined by your doctor.

Agrylin is a platelet-reducing agent. It works by decreasing the body's production of platelets, which helps to prevent blood clots.

Do NOT use Agrylin if:

• you are allergic to any ingredient in Agrylin


• you have severe liver disease

Contact your doctor or health care provider right away if any of these apply to you.

Before using Agrylin:

Some medical conditions may interact with Agrylin. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

• if you are pregnant, planning to become pregnant, or are breast-feeding


• if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines, foods, or other substances


• if you have heart, lung, liver, or kidney problems

Some MEDICINES MAY INTERACT with Agrylin. Tell your health care provider if you are taking any other medicines, especially any of the following:

• Sucralfate because it may decrease Agrylin's effectiveness


• Amrinone, aspirin, cilostazol, enoximone, milrinone, or olprinone because their actions and the risk of their side effects may be increased by Agrylin

This may not be a complete list of all interactions that may occur. Ask your health care provider if Agrylin may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Agrylin:

Use Agrylin as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Take Agrylin by mouth with or without food.


• Take Agrylin on a regular schedule to get the most benefit from it. It may take several weeks (4 to 12 weeks) before you get the full effect from Agrylin.


• If you miss a dose of Agrylin, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Agrylin.

Important safety information:

• Agrylin may cause drowsiness or dizziness. These effects may be worse if you take it with alcohol or certain medicines. Use Agrylin with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.


• Agrylin may cause dizziness, lightheadedness, or fainting; alcohol, hot weather, exercise, and fever can increase these effects. To prevent them, sit up or stand slowly, especially in the morning. Sit or lie down at the first sign of any of these effects.


• Agrylin may cause you to become sunburned more easily. Avoid the sun, sunlamps, or tanning booths until you know how you react to Agrylin. Use a sunscreen or wear protective clothing if you must be outside for more than a short time.


• Agrylin may reduce the number of clot-forming cells (platelets) in your blood. Avoid activities that may cause bruising or injury. Tell your doctor if you have unusual bruising or bleeding. Tell your doctor if you have dark, tarry, or bloody stools.


• Severe lung problems (eg, interstitial pneumonitis) have been reported in some patients who take Agrylin. This may develop within 1 week to several years after starting the medicine. Tell your doctor right away if you develop new or worsening shortness of breath or trouble breathing. Talk with your doctor for more information.


• Tell your doctor or dentist that you are using Agrylin before you have any medical or dental care, emergency care, or surgery.


• Lab tests, including liver function, kidney function, blood pressure, and complete blood cell counts, may be performed while you use Agrylin. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.


• If you may become pregnant, you must use an effective form of birth control while you take Agrylin. If you have questions about effective birth control, talk with your doctor.


• PREGNANCY and BREAST-FEEDING: Agrylin may cause harm to the fetus. Avoid becoming pregnant while taking Agrylin. If you think you may be pregnant, contact your doctor right away. It is not known if Agrylin is found in breast milk. Do not breast feed while taking Agrylin.

Possible side effects of Agrylin:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Back pain; cough; diarrhea; dizziness; drowsiness; gas; general body discomfort; headache; joint or muscle weakness; loss of appetite; nausea; stomach pain; tiredness; upset stomach; vomiting; weakness.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); blood in the urine, stools, or vomit; changes in vision; chest pain, especially if sharp or crushing; decreased urination; depression; easy bruising or bleeding; fainting; fast or irregular heartbeat; flu-like symptoms (eg, sore throat, fever, or chills); memory loss; mental or mood changes; numbness or tingling of your skin or of an arm or leg; one-sided weakness; pounding in the chest; seizures; severe stomach pain; sudden leg pain; sudden, severe headache, vomiting, dizziness, or fainting; shortness of breath; swelling of the hands, legs, or feet; trouble urinating; yellowing of the skin or eyes.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Agrylin side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include fast heartbeat; unusual bleeding and bruising; vomiting.

Proper storage of Agrylin:

Store Agrylin at 77 degrees F (25 degrees C). Brief storage at temperatures between 59 and 86 degrees F (15 and 30 degrees C) is permitted. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Agrylin out of the reach of children and away from pets.

General information:

• If you have any questions about Agrylin, please talk with your doctor, pharmacist, or other health care provider.


• Agrylin is to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.


• Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Agrylin. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Agrylin resources

• Agrylin Side Effects (in more detail)
• Agrylin Use in Pregnancy & Breastfeeding
• Drug Images
• Agrylin Drug Interactions
• Agrylin Support Group
• 0 Reviews for Agrylin - Add your own review/rating

• Agrylin Prescribing Information (FDA)


• Agrylin Advanced Consumer (Micromedex) - Includes Dosage Information


• Agrylin Concise Consumer Information (Cerner Multum)


• Agrylin Monograph (AHFS DI)


• Anagrelide Prescribing Information (FDA)


• Anagrelide Professional Patient Advice (Wolters Kluwer)

Compare Agrylin with other medications

• Chronic Myelogenous Leukemia
• Thrombocythemia

Agri-Cillin

Dosage Form: FOR ANIMAL USE ONLY
Agri-Cillin®

Injectable Antibiotic

NADA 065-010, Approved by FDA

For use in Cattle, Sheep, Swine and Horses.

PENICILLIN G PROCAINE

INJECTABLE SUSPENSION U.S.P.

READ ENTIRE BROCHURE CAREFULLY BEFORE USING THIS PRODUCT

Description:

Agri-Cillin is a suspension of penicillin G procaine in 100,250, and 500 mL multiple dose vials. Each mL is designed to provide 300,000 units of penicillin G as procaine in a stable suspension. Penicillin G procaine is an antibacterial agent which has activity against a variety of pathogenic organisms, mainly in the Gram-positive category.

Indications:

Agri-Cillin is indicated for treatment of bacterial pneumonia (shipping fever) caused by Pasteurella multocida in cattle and sheep, erysipelas caused by Erysipelothrix rhusiopathiae in swine, and strangles caused by Streptococcus equi in horses.

Directions for Use:

A thoroughly cleaned, sterile needle and syringe should be used for each injection (needles and syringes may be sterilized in boiling water for 15 minutes). Before withdrawing the solution from the bottle, disinfect the rubber cap top with 70% alcohol. The injection site should be similarly disinfected with alcohol. Needles of 16 to 18 gauge and 1 to 1.5 inches long are adequate for intramuscular injections.

In livestock intramuscular injections should be made by directing the needle of suitable gauge and length into the fleshy part of a thick muscle, such as rump, hip, or thigh region; avoid blood vessels and major nerves. Before injecting the solution, pull back gently on the plunger. If blood appears in the syringe, a blood vessel has been entered; withdraw the needle and select a different site.

Dosage:

Agri-Cillin is administered by the intramuscular route. The product is ready for injection after warming the vial to room temperature and shaking to ensure a uniform suspension.

The daily dose of penicillin is 3,000 units per pound of body weight (1 mL per 100 lbs body weight). Continue daily treatment until recovery is apparent and for at least one day after symptoms disappear, usually in two to three days.

Treatment should not exceed four consecutive days.

No more than 10 mL should be injected at any one site. Rotate injection sites for each succeeding treatment.

Care of Sick Animals:

The use of antibiotics in the management of diseases is based on an accurate diagnosis and an adequate course of treatment. When properly used in the treatment of diseases caused by penicillin-susceptible organisms, most animals treated with Agri-Cillin show a noticeable improvement within 24 to 48 hours. If improvement does not occur within this period of time, the diagnosis and course of treatment should be re-evaluated. It is recommended that the diagnosis and treatment of animal diseases be carried out by a veterinarian.

Since many diseases look alike but require different types of treatment, the use of professional veterinary and laboratory services can reduce treatment time, costs and needless losses. Good housing, sanitation and nutrition are important in the maintenance of healthy animals and are essential in the treatment of disease.

Residue Warnings:

Exceeding the daily dosage of 3,000 units per pound of body weight, administering for more than four consecutive days, or exceeding the maximum injection site volume per injection site may result in antibiotic residues beyond the withdrawal time.

Milk taken from treated dairy animals within 48 hours after the last treatment must not be used for food. Discontinue use of this drug for the following time period before treated animals are slaughtered for food:

Cattle-14 days, Sheep-9 days, Swine - 7 days.

A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal.

Warning:

Do not use in horses intended for human consumption. Not for use in humans. Keep out of reach of children.

Precautions:

Intramuscular injection in cattle, sheep, and swine may result in a local tissue reaction which persists beyond the withdrawal period of 14 days (cattle), 9 days (sheep), or 7 days (swine). This may result in trim loss of edible tissue at slaughter.

Allergic or anaphylactic reactions, sometimes fatal, have been known to occur in animals hypersensitive to penicillin and procaine. Such reactions can occur unpredictably with varying intensity. Animals administered penicillin G procaine should be kept under close observation for at least one half hour. Should allergic or anaphylactic reactions occur, discontinue use of the product and call a veterinarian. If respiratory distress is severe, immediate injection of epinephrine or antihistamine following manufacturer's recommendations may be necessary.

As with all antibiotic preparations, use of this drug may result in overgrowth of nonsusceptible organisms, including fungi. A lack of response by the treated animal, or the development of new signs or symptoms suggest that an overgrowth of nonsusceptible organisms has occurred. In such instances, consult your veterinarian.

It is advisable to avoid giving penicillin in conjunction with bacteriostatic drugs such as tetracyclines.

Storage Conditions:

Agri-Cillin should be stored between 2 to 8°C (36 to 46°F).

Restricted Drug - California.

Use Only as Directed.

Made in the UK.

Norbrook Laboratories Limited

Newry, Northern Ireland

Distributed by:

Agri Laboratories, Ltd.

St. Joseph, MO 64503

www.AgriLabs.com

006107I01

® Registered Trademark of Agri Laboratories, Ltd.

AgriLabs®

Making A Healthy Difference®

Principal Display Panel – 500 mL Vial Label

Agri-Cillin®

NDC 57561 065 05

STERILE PENICILLIN G PROCAINE

INJECTABLE SUSPENSION U.S.P.

INJECTABLE ANTIBIOTIC

IN AQUEOUS SUSPENSION

300,000 UNITS PER mL

ANTIBIOTIC

FOR INTRAMUSCULAR INJECTION ONLY

NADA 065-010, APPROVED BY FDA

Net Contents: 500 mL

AgriLabs®

Making A Healthy Difference®

AGRICILLIN  penicillin g procaine  injection, suspension

Product Information Product Type OTC ANIMAL DRUG NDC Product Code (Source) 57561-065 Route of Administration INTRAMUSCULAR DEA Schedule

Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength penicillin G procaine (penicillin G) penicillin G procaine 300000 [USP'U]  in 1 mL

Inactive Ingredients Ingredient Name Strength No Inactive Ingredients Found

Product Characteristics Color      Score      Shape Size Flavor Imprint Code Contains

Packaging # NDC Package Description Multilevel Packaging 1 57561-065-02 100 mL In 1 VIAL, GLASS None 2 57561-065-04 250 mL In 1 VIAL, GLASS None 3 57561-065-05 500 mL In 1 VIAL, GLASS None

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NADA	NADA065010	01/01/2004

Labeler - Agri Laboratories Limited (155594450)

Registrant - Norbrook Laboratories Limited (214580029)

Establishment
Name	Address	ID/FEI	Operations
Station Works		214580029	MANUFACTURE, ANALYSIS

Establishment
Name	Address	ID/FEI	Operations
Carnbane Industrial Estate		211218325	MANUFACTURE

Revised: 02/2011Agri Laboratories Limited

AK-Neo-Dex

Generic Name: neomycin and dexamethasone ophthalmic (nee oh MYE sin DEX a METH a sone off THAL mik)

Brand Names:

What is AK-Neo-Dex (neomycin and dexamethasone ophthalmic)?

Neomycin is an antibiotic. It is used to treat bacterial infections.

Dexamethasone is a steroid. It is used to treat the inflammation associated with bacterial infections of the eye.

Neomycin and dexamethasone ophthalmic is used to treat bacterial infections of the eyes.

Neomycin and dexamethasone ophthalmic may also be used for purposes other than those listed in this medication guide.

What is the most important information I should know about AK-Neo-Dex (neomycin and dexamethasone ophthalmic)?

Contact your doctor if your symptoms begin to get worse or if you do not see any improvement in your condition after a few days.

Do not touch the dropper or tube opening to any surface, including your eyes or hands. The dropper or tube opening is sterile. If it becomes contaminated, it could cause an infection in your eye.

Apply light pressure to the inside corner of your eye (near your nose) after each drop to prevent the fluid from draining down your tear duct.

Who should not use AK-Neo-Dex (neomycin and dexamethasone ophthalmic)?

Do not use neomycin and dexamethasone ophthalmic if you have a viral or fungal infection in your eye. It is used to treat infections caused by bacteria only. Neomycin and dexamethasone ophthalmic is in the FDA pregnancy category C. This means that it is not known whether it will harm an unborn baby. Do not use this medication without first talking to your doctor if you are pregnant. It is also not known whether neomycin and dexamethasone ophthalmic passes into breast milk. Do not use this medication without first talking to your doctor if you are breast-feeding a baby.

How should I use AK-Neo-Dex (neomycin and dexamethasone ophthalmic)?

Use neomycin and dexamethasone ophthalmic eyedrops or ointment exactly as directed by your doctor. If you do not understand these directions, ask your pharmacist, nurse, or doctor to explain them to you.

Wash your hands before and after using your eyedrops or ointment.

To apply the eyedrops:

• 
  

  Tilt your head back slightly and pull down on your lower eyelid. Position the dropper above your eye. Look up and away from the dropper. Squeeze out a drop and close your eye. Apply gentle pressure to the inside corner of your eye (near your nose) for about 1 minute to prevent the liquid from draining down your tear duct. Repeat the process in the other eye if your doctor has prescribed drops in both eyes. If you are using more than one drop in the same eye, repeat the process with about 5 minutes between drops.

  
  

To apply the ointment:

• 
  

  Hold the tube in your hand for a few minutes to warm it up so that the ointment comes out easily. Tilt your head back slightly and pull down gently on your lower eyelid. Apply a thin film of the ointment into your lower eyelid. Close your eye and roll your eyeball around in all directions for 1 to 2 minutes. Repeat the process in the other eye if your doctor has prescribed ointment in both eyes.

  
  

If you are applying another eye medication, allow at least 10 minutes before your next application.

Do not touch the dropper or tube opening to any surface, including your eyes or hands. The dropper or tube opening is sterile. If it becomes contaminated, it could cause an infection in your eye. Do not use any eyedrop that is discolored or has particles in it. Store neomycin and dexamethasone ophthalmic at room temperature away from moisture and heat. Keep the bottle or tube properly capped.

What happens if I miss a dose?

Apply the missed dose as soon as you remember. However, if it is almost time for your next regularly scheduled dose, skip the missed dose and apply the next one as directed. Do not use a double dose of this medication.

What happens if I overdose?

An overdose of this medication is unlikely to occur. If you do suspect an overdose, wash the eye with water and call an emergency room or poison control center near you. If the drops or ointment have been ingested, drink plenty of fluid and call an emergency center for advice.

What should I avoid while using AK-Neo-Dex (neomycin and dexamethasone ophthalmic)?

Do not touch the dropper or tube opening to any surface, including your eyes or hands. The dropper or tube opening is sterile. If it becomes contaminated, it could cause an infection in your eye. Use caution when driving, operating machinery, or performing other hazardous activities. Neomycin and dexamethasone ophthalmic may cause blurred vision. If you experience blurred vision, avoid these activities.

Use caution with contact lenses. Wear them only if your doctor approves. After applying this medication, wait at least 15 minutes before inserting contact lenses.

Avoid other eye medications unless your doctor approves.

AK-Neo-Dex (neomycin and dexamethasone ophthalmic) side effects

Serious side effects are not expected with this medication.

Some burning, stinging, irritation, itching, redness, blurred vision, eyelid itching, eyelid swelling, or sensitivity to light may occur.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect AK-Neo-Dex (neomycin and dexamethasone ophthalmic)?

Avoid other eye medications unless they are approved by your doctor.

Before using this medication, tell your doctor if you are taking an oral steroid medication such as prednisone (Deltasone, Orasone, others).

Drugs other than those listed here may also interact with neomycin and dexamethasone ophthalmic. Talk to your doctor and pharmacist before taking any prescription or over-the-counter medicines.

More AK-Neo-Dex resources

• AK-Neo-Dex Side Effects (in more detail)
• AK-Neo-Dex Use in Pregnancy & Breastfeeding
• AK-Neo-Dex Drug Interactions
• AK-Neo-Dex Support Group
• 0 Reviews for AK-Neo-Dex - Add your own review/rating

Compare AK-Neo-Dex with other medications

• Blepharitis
• Conjunctivitis, Bacterial
• Keratitis
• Keratoconjunctivitis
• Uveitis

Where can I get more information?

• Your pharmacist has additional information about neomycin and dexamethasone ophthalmic written for health professionals that you may read.

See also: AK-Neo-Dex side effects (in more detail)

AK-NaCl

Generic Name: sodium chloride (Ophthalmic route)

SOE-dee-um KLOR-ide

Commonly used brand name(s)

In the U.S.

• AK-NaCl


• Muro-128


• OcuFresh


• Sochlor

In Canada

• Cordema


• Eye Wash


• In A Wink Daily Cleaner


• In A Wink Neutralizing Rinse

Available Dosage Forms:

• Solution


• Ointment

Therapeutic Class: Osmotherapy Agent

Uses For AK-NaCl

Hypertonic sodium chloride solution for the eye is used to draw water out of a swollen cornea. The extra water in the cornea can cause your vision to be poor. You may also see halos or rings around point light sources. The cornea is the clear cover over the colored part of your eye.

This medicine is available only with your doctor's prescription.

Before Using AK-NaCl

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:

Allergies

Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.

Pediatric

Although there is no specific information comparing use of hypertonic sodium chloride in children with use in other age groups, this medicine is not expected to cause different side effects or problems in children than it does in adults.

Geriatric

Many medicines have not been studied specifically in older people. Therefore, it may not be known whether they work exactly the same way they do in younger adults or if they cause different side effects or problems in older people. There is no specific information comparing use of hypertonic sodium chloride in the elderly with use in other age groups.

Interactions with Medicines

Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine.

Interactions with Food/Tobacco/Alcohol

Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.

Proper Use of sodium chloride

This section provides information on the proper use of a number of products that contain sodium chloride. It may not be specific to AK-NaCl. Please read with care.

To use:

• The bottle is only partially full to provide proper drop control.


• First, wash your hands. Then tilt the head back and pull the lower eyelid away from the eye to form a pouch. Drop the medicine into the pouch and gently close the eyes. Do not blink. Keep the eyes closed for 1 or 2 minutes to allow the medicine to be absorbed.


• If you think you did not get the drop of medicine into your eye properly, use another drop.


• Immediately after using the eye drops, wash your hands to remove any medicine that may be on them.


• To keep the medicine as germ-free as possible, do not touch the applicator tip to any surface (including the eye). Also, keep the container tightly closed. Serious damage to the eye and possible loss of vision may result from using contaminated eye drops.

Dosing

The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.

The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.

• For ophthalmic solution (eye drops) dosage form:
  
  • For swelling of the cornea:
    
    • Adults—Use 1 drop every three or four hours.
    
    
    • Children—Use and dose must be determined by your doctor.
    
    
  
  

Missed Dose

If you miss a dose of this medicine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.

Storage

Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.

Keep out of the reach of children.

Do not keep outdated medicine or medicine no longer needed.

Ask your healthcare professional how you should dispose of any medicine you do not use.

Precautions While Using AK-NaCl

Use only under the advice and supervision of a doctor.

If you experience eye pain, changes in vision, continued redness or irritation of the eye, or if your symptoms continue for more than 3 days or become worse, check with your doctor.

Importance of not contaminating the product. Do not touch the tip of the container to the eye or any surface.

Do not use if the solution changes color or becomes cloudy.

Replace cap after each use. Store container upright.

AK-NaCl Side Effects

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More Common

• temporary burning sensation of the eye


• temporary eye irritation

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.

The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.

More AK-NaCl resources

• AK-NaCl Support Group
• 0 Reviews · Be the first to review/rate this drug

• Altachlore Drops MedFacts Consumer Leaflet (Wolters Kluwer)


• Sodium Chloride Monograph (AHFS DI)

Agrylin

Generic Name: Anagrelide hydrochloride
Class: Platelet-reducing Agents
VA Class: BL400
Chemical Name: 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2(3H)-one monohydrochloride monohydrate
CAS Number: 58579-51-4; 68475-42-3

Introduction

Platelet-reducing agent; imidazoquinazoline derivative.^{1 4 5 7 9 10 11 12 14 15 16 17 18 22 23 24 26 31 32}

Uses for Agrylin

Thrombocythemia

Reduction of elevated platelet counts and associated risk of thromboembolic and hemorrhagic events in patients with thrombocythemia secondary to essential thrombocythemia (ET) and other myeloproliferative disorders.^{1 3 7 13 14 15 17 18 23} Has been designated an orphan drug by FDA for the treatment of ET.²

Management of ET generally based on a risk-stratification approach.^{3 7 11 14 16 19 20 22 25 27 31 32} Treatment with a cytoreductive agent (e.g., anagrelide, hydroxyurea) usually reserved for patients at high risk (i.e., age >60 years, previous history of thrombosis, and/or platelet count ≥1,500,000/mm³) of developing thromboembolic and/or hemorrhagic complications.^{3 7 9 11 12 13 14 16 20 25 31 32} Some clinicians also recommend cytoreductive therapy in intermediate-risk ET patients (e.g., 40–60 years of age, platelet count >1,000,000/mm³, and cardiovascular risk factor [smoking, arterial hypertension, hypercholesterolemia, or diabetes mellitus] or familial thrombophilia).^{27 31 32}

Hydroxyurea (often combined with low-dose aspirin) generally considered drug of choice in high-risk patients with ET because of proven efficacy and infrequent acute toxicity.^{3 6 7 11 14 17 20 21 22 25 27 30 32} However, because of potential leukemogenic effects with hydroxyurea when used long term or sequentially with other cytotoxic drugs,^{3 5 7} anagrelide or interferon alfa suggested as alternative therapy in high-risk patients, particularly younger patients (<40–60 years of age), and in those who do not respond to or cannot tolerate hydroxyurea.^{3 5 7 9 17 22 24 25 27 31 32} Consider cautious use of low-dose aspirin concomitantly with anagrelide based on relative risks of thrombosis and arterial hemorrhage in individual patients.^{3 5 6 11 27 31 32} (See Specific Drugs or Foods under Interactions.)

Agrylin Dosage and Administration

General

• 
  

  Initiate therapy under close supervision of a clinician.¹

  
  


• 
  

  Monitor platelet counts every 2 days for 1 week following initiation of therapy, then at least weekly thereafter until maintenance dosage established.^{1 23}

  
  

Administration

Oral Administration

Administer orally without regard to meals.¹

Dosage

Available as anagrelide hydrochloride; dosage expressed in terms of anagrelide.¹

Pediatric Patients

Thrombocythemia

Oral

Children and adolescents 7–14 years of age: Initially, 0.5 mg daily.¹ Initial dosages up to 0.5 mg 4 times daily have been used.¹

Maintain initial dosage for ≥1 week, then adjust to lowest effective dosage that will maintain platelet counts <600,000/mm³ or ideally within normal range.^{1 17} Usual maintenance dosage is 1.5–3 mg daily.^{1 17 18}

Increase dosage by ≤0.5 mg daily in any 1-week period.^{1 17}

Continue therapy indefinitely if adequate response achieved.^{17 23}

Adults

Thrombocythemia

Oral

Initially, 0.5 mg 4 times daily or 1 mg twice daily recommended by manufacturer.¹ Lower dosages (e.g., 0.5 mg twice daily) have been used and may improve tolerability.⁵

Maintain initial dosage for ≥1 week, then adjust to lowest effective dosage that will maintain platelet counts <600,000/mm³ or ideally within normal range (e.g., 150,000–400,000/mm³).^{1 17} Usual maintenance dosage is 1.5–3 mg daily.^{1 13 17 22}

Increase dosage by ≤0.5 mg daily in any 1-week period.^{1 17 22}

Continue therapy indefinitely if adequate response achieved.^{17 23}

Prescribing Limits

Pediatric Patients

Thrombocythemia

Oral

Children and adolescents 7–14 years of age: Maximum 10 mg daily or 2.5 mg as a single dose.¹

Adults

Thrombocythemia

Oral

Maximum 10 mg daily or 2.5 mg as a single dose.¹

Special Populations

Hepatic Impairment

In patients with moderate hepatic impairment, reduce initial dosage to 0.5 mg daily and maintain for ≥1 week.¹ Increase dosage by ≤0.5 mg daily in any 1-week period.¹ (See Hepatic Impairment under Cautions.)

Contraindicated in severe hepatic impairment.¹

Renal Impairment

Dosage adjustment not required in patients with renal impairment.¹

Cautions for Agrylin

Contraindications

Severe hepatic impairment.¹

Warnings/Precautions

Warnings

Cardiovascular Effects

Adverse cardiovascular effects (e.g., vasodilation, tachycardia, palpitations, edema, CHF) reported with usual dosages of anagrelide, including rare cases of sudden death.^{1 5 16 17 18 26} Assess risk versus benefits of therapy.^{1 16 17} Use with caution, if at all, in patients with known or suspected cardiovascular disease.^{1 5 13 15 16 17 18 22 23 24} Evaluate cardiac status prior to and during therapy.^{1 5 13 16 17} Consider reduced dosages.⁵ Some clinicians recommend immediate discontinuance of therapy if any evidence of cardiac dysfunction occurs.^{5 26}

Temporary decreases in BP reported, usually during treatment initiation; BP appears to normalize during maintenance therapy.^{5 9 17 23 24}

General Precautions

Laboratory Monitoring

Monitor CBCs, liver function tests, and renal function tests while platelet counts are being decreased, usually during first 2 weeks of therapy.¹

To assess response to therapy and prevent thrombocytopenia, monitor platelet counts every 2 days for first week of therapy, then at least weekly thereafter until maintenance dosage achieved.^{1 23}

Rebound Thrombocythemia

A rapid (e.g., within 4 days) increase in platelet count generally is observed when anagrelide is discontinued or interrupted.^{1 5 16 17 18 23} Continue treatment indefinitely (if adequate response achieved) to prevent rebound thrombocythemia.^{17 23}

Anemia

Decreases in hemoglobin and hematocrit (anemia) reported, usually with long-term use.^{1 5 9 10 12 13 16 17 18 24 27}

Bleeding Tendency

Concomitant use with aspirin may increase bleeding tendency.^{3 5 6 9} (See Specific Drugs and Foods under Interactions.) Use caution with such combined therapy.^{3 5 6} Some clinicians suggest that aspirin not be used concomitantly with anagrelide in patients with history of bleeding.³

Renal Effects

Renal impairment reported in a few patients following treatment with anagrelide; most patients had preexisting renal impairment.^{1 17 23} Monitor renal function while platelet counts are being decreased.¹

Fetal/Neonatal Morbidity

Safety of use during pregnancy not established; embryotoxicity and fetotoxicity demonstrated in animals.¹ Generally not recommended in pregnant women unless potential benefits outweigh possible risks to fetus.^{1 5 11 16 22} Women of childbearing potential should avoid pregnancy and use contraception during therapy.^{1 5}

Specific Populations

Pregnancy

Category C.¹

Lactation

Not known whether anagrelide is distributed into human milk.¹ Discontinue nursing or drug because of potential risk in nursing infants.^{1 5}

Pediatric Use

Evaluated in a limited number of children and adolescents 7–14 years of age with thrombocythemia secondary to myeloproliferative disorders;^{1 28 29} preliminary data suggest no overall differences in dosage or adverse effects relative to adults.¹

Geriatric Use

Response in patients ≥65 years of age does not appear to differ from that in younger adults.¹ Use with caution because of age-related decreases in hepatic, renal, and/or cardiac function.^{1 5 16 22}

Hepatic Impairment

Extensively metabolized in liver; possible increased systemic exposure to anagrelide in patients with hepatic impairment.^{1 9} (See Elimination: Special Populations, under Pharmacokinetics.)

Weigh risks of therapy against potential benefits in patients with mild to moderate hepatic impairment.¹ Reduce dosage and carefully monitor for adverse cardiovascular effects or other manifestations of toxicity.^{1 17 22 23} (See Hepatic Impairment under Dosage and Administration and see Cardiovascular Effects under Cautions.)

Contraindicated in patients with severe hepatic impairment.¹

Renal Impairment

Closely monitor patients with known or suspected renal impairment for cardiovascular effects or other manifestations of toxicity.^{1 17 23}

Common Adverse Effects

Headache,^{1 3 5 7 9 10 16 17 18 23 24} palpitations,^{1 3 5 7 9 10 16 17 18 23 24} diarrhea,^{1 3 5 7 9 10 17 18 23 24} asthenia,^{1 9 23} edema,^{1 5 9 10 16 17 18 23 24} nausea,^{1 7 9 18 23 24} abdominal pain,^{1 9 17 18 23 24} dizziness,^{1 9 16 18 23 24} pain,^{1 9} dyspnea,^{1 9} flatulence,^{1 9 18} vomiting,^{1 9 23} fever,^{1 9} peripheral edema,^{1 9} rash,^{1 9} chest pain,^{1 23} anorexia,^{1 9} tachycardia,^{1 7 9 16 18 23 24} pharyngitis,^{1 9} malaise,^{1 9 23} cough,^{1 9} paresthesia,^{1 9} back pain,¹ pruritus,^{1 9} dyspepsia.^{1 9}

Interactions for Agrylin

Metabolized partially by CYP1A2; inhibits CYP1A2 to a limited extent.¹

Inhibits phosphodiesterase (PDE) type 3.^{1 4 5 9 10 11 16 18 22 23}

Drugs Affecting Hepatic Microsomal Enzymes

Inhibitors of CYP1A2: Potential pharmacokinetic interaction (decreased clearance of anagrelide).^{1 9 22}

Drugs Metabolized by Hepatic Microsomal Enzymes

CYP1A2 substrates: Potential pharmacokinetic interaction (decreased clearance of substrate).^{1 22}

Specific Drugs or Foods

Drug or Food	Interaction	Comments
Aspirin	No clinically important interaction observed in vivo;1 however, potential for increased risk of bleeding due to additive platelet inhibition3 5 9 10 11 14 22 27	Use concomitantly with caution, considering individual risks of thrombosis and bleeding; carefully monitor for bleeding3 5 11 27
Digoxin	Pharmacokinetic interaction unlikely1 9 22
Fluvoxamine	Possible decreased clearance of anagrelide1 9 22
Grapefruit juice	Possible decreased clearance of anagrelide 9 22
Omeprazole	Possible decreased clerance of anagrelide 22
PDE type 3 inhibitors (e.g., amrinone, cilostazol, milrinone)	Possible additive pharmacologic effects1 9 22	Use with caution22
Sucralfate	Possible decreased absorption of anagrelide1
Theophylline	Possible decreased clearance of theophylline 1 9 22
Warfarin	Pharmacokinetic interaction unlikely1 9 22

Agrylin Pharmacokinetics

Absorption

Bioavailability

Well absorbed following oral administration. ⁹

Following oral administration, peak plasma concentrations attained within 1–2 hours.^{5 9 22 23 24}

No evidence of drug accumulation following multiple dosing.^{1 9 29}

Onset

Platelet counts usually begin to decrease within 7–14 days.^{1 5 9 10 17 22} Complete response (e.g., platelet count ≤600,000/mm³) generally achieved within 4–12 weeks.¹

Food

Food decreases peak plasma concentrations by 14% and increases AUC by 20%; not clinically important.^{1 5 9}

Special Populations

In children and adolescents 7–14 years of age, AUC and peak plasma anagrelide concentrations lower than those in adults 16–86 years of age.¹

Distribution

Extent

Distributes extensively into large peripheral compartment.²⁴

Crosses placenta.⁵

Elimination

Metabolism

Extensively metabolized in liver to at least 4 metabolites, including an active hydroxylated derivative (3-hydroxyanagrelide).^{1 4 5 9 16 17 22 23 24}

Undergoes first-pass metabolism by CYP1A2 to 3-hydroxyanagrelide.⁹

Elimination Route

Excreted principally in urine as metabolites (>70%) and unchanged drug (<1%).^{5 9 16 17 22 23 24} Approximately 10% excreted in feces through bile.^{5 24}

Half-life

Anagrelide: Approximately 1.3 hours after a single 0.5-mg dose under fasting conditions.^{1 17 29}

3-Hydroxyanagrelide: Approximately 3 hours.²⁹

Special Populations

Systemic exposure increased eightfold in patients with moderate hepatic impairment compared with that in healthy individuals.^{1 9}

Severe renal impairment (Cl_cr <30 mL/minute) does not appear to affect pharmacokinetics of anagrelide.^{1 9}

Possible decreased clearance and prolonged half-life in geriatric patients.⁵

Stability

Storage

Oral

Tablets

25°C in light-resistant container; may be exposed to 15–30°C.¹

ActionsActions

• 
  

  Exact mechanism of action not fully elucidated;^{1 4 9 12 17 22 23} thought to reduce platelet counts in a dose-related manner by selectively inhibiting megakaryocyte maturation during postmitotic stage of development.^{1 4 6 9 10 12 13 14 15 16 17 18 19 22 23 23 24} Reduces size and ploidy of megakaryocytes, but does not appear to affect platelet function or bleeding time.^{1 5 9 15 16 17 19 22 24 23}

  
  

• 
  

  Acts selectively on megakaryocytes with minimal or no effect on other blood-cell precursors.^{3 4 5 11 13 14 17 18 23 24} Current data suggest no long-term leukemogenicity.^{3 5 17 23}

  
  


• 
  

  Inhibits phospholipase A₂ and phosphodiesterase (PDE) type 3 activity in platelets; results in increased concentrations of cyclic adenosine monophosphate (cAMP).^{1 4 5 9 10 11 16 18 22 23 24 29} Such increases in cAMP may produce an anti-aggregating effect on platelets at dosages substantially higher than those required to cause thrombocytopenia.^{1 3 4 5 6 8 9 11 15 16 17 18 23 24}

  
  


• 
  

  Exerts positive inotropic and vasodilatory effects through inhibition of cAMP PDE type 3 in myocardium;^{5 9 11 16 17 18 22 23 24 26} such actions may result in adverse cardiovascular effects.^{9 10 16 17 23 26}

  
  

Advice to Patients

• 
  

  Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed. ¹ Advise women of childbearing potential to avoid pregnancy and use effective contraception while taking anagrelide.¹ If pregnancy occurs, apprise patient of potential risk to fetus.¹

  
  


• 
  

  Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses (e.g., liver disease).¹

  
  


• 
  

  Importance of informing patients of other important precautionary information.¹ (See Cautions.)

  
  

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Anagrelide Hydrochloride

Routes	Dosage Forms	Strengths	Brand Names	Manufacturer
Oral	Capsules	0.5 mg (of anagrelide)*	Agrylin	Shire
			Anagrelide Hydrochloride Capsules	Barr, Mylan, Sandoz, Teva
		1 mg (of anagrelide)*	Agrylin	Shire
			Anagrelide Hydrochloride Capsules	Barr, Mylan, Sandoz, Teva

Comparative Pricing

This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 04/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.

Agrylin 0.5MG Capsules (SHIRE US INC.): 50/$329.97 or 150/$970.02

Agrylin 1MG Capsules (SHIRE US INC.): 50/$545.99 or 150/$1621.95

Anagrelide HCl 0.5MG Capsules (IVAX PHARMACEUTICALS INC.): 30/$79.98 or 90/$235.97

Anagrelide HCl 1MG Capsules (IVAX PHARMACEUTICALS INC.): 50/$109.99 or 150/$310.02

Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.

The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions September 01, 2008. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.

References

1. Shire. Agrylin (anagrelide hydrochloride) capsules prescribing information. Wayne, PA; 2004 Dec.

2. Food and Drug Administration. Orphan designations pursuant to Section 526 of the Federal Food and Cosmetic Act as amended by the Orphan Drug Act (P.L. 97-414). Rockville, MD. From FDA web site. Accessed 2007 Nov 30.

3. Steurer M, Gastl G, Jedrzejczak WW et al. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile. Cancer. 2004; 101:2239-46. [PubMed 15476273]

4. Wang G, Franklin R, Hong Y et al. Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures. Br J Pharmacol. 2005; 146:324-32. [PubMed 16041400]

5. Petrides PE. Anagrelide: a decade of clinical experience with its use for the treatment of primary thrombocythaemia. Expert Opin Pharmacother. 2004; 5:1781-98. [PubMed 15264993]

6. Harrison CN, Campbell PJ, Buck G et al for the United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005; 353:33-45. [PubMed 16000354]

7. Penninga EI, Bjerrum OW. Polycythaemia vera and essential thrombocythaemia: current treatment strategies. Drugs. 2006; 66:2173-87. [PubMed 17137402]

8. Petrides PE. Anagrelide: What was new in 2004 and 2005? Semin Thromb Hemost. 2006; 32:399-408.

9. Wagstaff AJ, Keating GM. Anagrelide: a review of its use in the management of essential thrombocythaemia. Drugs. 2006; 66:111-31. [PubMed 16398570]

10. Birgegard G. Anagrelide treatment in myeloproliferative disorders. Semin Thromb Hemost. 2006; 32:260-6. [PubMed 16673280]

11. Campbell PJ, Green AR. Management of polycythemia vera and essential thrombocythemia. Hematology Am Soc Hematol Educ Program. 2005; 201-8.

12. Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood. 2001; 97:863-6. [PubMed 11159509]

13. Mazzucconi MG, Redi R, Bernasconi S et al. A long-term study of young patients with essential thrombocythemia treated with anagrelide. Haematologica. 2004; 89:1306-13. [PubMed 15531452]

14. Barbui T, Finazzi G. When and how to treat essential thrombocythemia. N Engl J Med. 2005; 353:85-6. [PubMed 16000360]

15. Laguna MS, Kornblihtt LI, Marta RF et al. Effectiveness of anagrelide in the treatment of symptomatic patients with essential thrombocythemia. Clin Appl Thromb Hemost. 2000; 6:157-61. [PubMed 10898276]

16. Brooks WG, Stanley DD, Goode JV. Role of anagrelide in the treatment of thrombocytosis. Ann Pharmacother. 1999; 33:1116-8. [PubMed 10534225]

17. Oertel MD. Anagrelide, a selective thrombocytopenic agent. Am J HealthSyst Pharm. 1998; 55:1979-86.

18. Anagrelide Study Group. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med. 1992; 92:69-76. [PubMed 1731512]

19. Thiele J, Kvasnicka HM, Schmitt-Graeff A. Effects of anagrelide on megakaryopoiesis and platelet production. Semin Thromb Hemost. 2006; 32:352-61. [PubMed 16810611]

20. Tefferi A. Essential thrombocythemia: scientific advances and current practice. Curr Opin Hematol. 2006; 13:93-8. [PubMed 16456375]

21. American Society of Hematology. Old treatment remains best option for patients with blood disorder [Abstract 6]. Washington, DC; 2004 Dec 5. Press release.

22. Harrison CN. Anagrelide for control of thrombocytosis due to myeloproliferative disorders. Future Oncol. 2005; 1:609-18. [PubMed 16556037]

23. Pescatore SL, Lindley C. Anagrelide: a novel agent for the treatment of myeloproliferative disorders. Expert Opin Pharmacother. 2000; 1:537-46. [PubMed 11249536]

24. Spencer CM, Brogden RN. Anagrelide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of thrombocythaemia. Drugs. 1994; 47:809-22. [PubMed 7520859]

25. Finazzi G, Barbui T. Expertise-based management in essential thrombocythemia and polycythemia vera. Cancer J. 2007; 13:372-6. [PubMed 18032974]

26. Engel PJ, Johnson H, Baughman RP et al. High-output heart failure associated with anagrelide therapy for essential thrombocytosis. Ann Intern Med. 2005; 143:311-3. [PubMed 16103481]

27. Gisslinger H. Update on diagnosis and management of essential thrombocythemia. Semin Thromb Hemost. 2006; 32:430-6. [PubMed 16810619]

28. Chintagumpala MM, Kennedy LL, Steuber CP. Treatment of essential thrombocythemia with anagrelide. J Pediatr. 1995; 127:495-8. [PubMed 7658287]

29. Shire, Wayne, PA: Personal communication.

30. Barosi G, Besses C, Birgegard G et al. A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Leukemia. 2007; 21:277-80. [PubMed 17251900]

31. Briere JB. Essential thrombocythemia. Orphanet J Rare Dis.. 2007; 2:3. Available from website. Accessed 2008 Jan 2.

32. Barbui T, Barosi G, Grossi A et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica. 2004; 89:215-32. [PubMed 15003898]

More Agrylin resources

• Agrylin Side Effects (in more detail)
• Agrylin Use in Pregnancy & Breastfeeding
• Drug Images
• Agrylin Drug Interactions
• Agrylin Support Group
• 0 Reviews for Agrylin - Add your own review/rating

• Agrylin Prescribing Information (FDA)


• Agrylin MedFacts Consumer Leaflet (Wolters Kluwer)


• Agrylin Concise Consumer Information (Cerner Multum)


• Agrylin Advanced Consumer (Micromedex) - Includes Dosage Information


• Anagrelide Prescribing Information (FDA)


• Anagrelide Professional Patient Advice (Wolters Kluwer)

Compare Agrylin with other medications

• Chronic Myelogenous Leukemia
• Thrombocythemia